<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T08:48:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/s6c52nhshb.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/s6c52nhshb.1</identifier>
                <datestamp>2025-09-25T15:18:09Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Torreno, Fernan</dc:creator>
    <dc:title>Meta-Analysis Dataset: Effectiveness of HIV Pre-Exposure Prophylaxis (PrEP) Across 100 Studies (2000–2025)</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>This dataset presents a comprehensive meta-analysis of HIV pre-exposure prophylaxis (PrEP) effectiveness across 100 studies conducted between 2000 and 2025. The included studies represent a mix of randomized controlled trials (62 studies) and observational studies (38 studies) conducted globally, encompassing diverse populations at heightened risk of HIV infection:
	•	Men who have sex with men (MSM) (42 studies)
	•	Serodiscordant couples (18 studies)
	•	People who inject drugs (PWID) (12 studies)
	•	High-risk heterosexuals (28 studies)

PrEP interventions covered in the analysis include both oral formulations (84 studies) and long-acting injectable cabotegravir (CAB) (16 studies).

The study adhered to PRISMA guidelines for systematic review and meta-analysis. A total of 2,134 records were initially identified, with 100 studies meeting inclusion criteria after full-text screening. Outcomes assessed include:
	•	HIV incidence reduction (relative risk, confidence intervals)
	•	PrEP adherence metrics (pill count, electronic monitoring, plasma levels, self-report)
	•	Safety and tolerability outcomes (GI events, renal function, bone density, injection-site reactions)
	•	Risk of bias assessment using the Cochrane tool (for RCTs) and Newcastle-Ottawa Scale (for observational studies).

Findings highlight consistently high effectiveness among MSM (≈90% risk reduction with high adherence), substantial benefit in serodiscordant couples (≈75%), moderate protection among PWID (≈49%), and variable efficacy in heterosexual populations (46–77%). Adherence emerged as a critical determinant of effectiveness.

This dataset provides a modular synthesis matrix and detailed evidence tables that can be used by researchers, clinicians, and policymakers to optimize PrEP implementation strategies, improve adherence support, and inform public health guidelines.</dc:description>
    <dc:subject>Socialization and Social Development</dc:subject>
    <dc:contributor id="https://orcid.org/0009-0001-6161-6437">Flores , Frincess</dc:contributor>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/s6c52nhshb.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/s6c52nhshb.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/s6c52nhshb</dc:relation>
    <dc:date>2025-09-25T15:18:09Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
